Mer­ck asks EMA to reeval­u­ate re­ject­ed Covid-19 an­tivi­ral

Mer­ck is seek­ing a reeval­u­a­tion of the Eu­ro­pean Med­i­cines Agency’s (EMA) re­jec­tion of the phar­ma’s block­buster Covid-19 pill, known as Lagevrio (mol­nupi­ravir), which has served …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.